Please ensure Javascript is enabled for purposes of website accessibility
Home > Featured Products > Stable Cell Lines

HEK293T Human CLDN18.2 Stable Cell Line (HX126818)

HEK293T Human CLDN18.2 Stable Cell Line
HEK293T Human CLDN18.2 Stable Cell Line
Price(USD):
Spec:
  • 1 ml
Number:
Get quote
  • Overview

  • Images

  • References

  • Datasheet

Overview
Catalog No.HX126818
Description
HEK293T Human CLDN18.2 Stable Cell Line (HX126818) is a stable cell line expressing CLDN18.2. Engineered for consistent, high-level target expression in research applications.
Highlights
  • Stable Expression — Engineered for consistent, high-level target expression.
AccessionP56856
ApplicationsFCM
SpeciesHuman
Host species HEK293T
Target CLDN18.2
Detection method Colorimetric
Sample type Plasma, Serum
Assay type Quantitative
Range 1.56 - 100 ng/mL
Sensitivity 0.25 ng/mL
Recovery 80-120%
Properties Growth Properties: Adherent; Selection Marker: Puromycin (1 μg/mL)
Shipping 2-8 ℃
Stability and Storage Frozen in liquid nitrogen.
Specifications 1 vial contains at least 2×10^6 cells in 1 mL Freeze Medium
Background

Claudin-18 (CLDN18.2) is a ~27 kDa protein. Involved in alveolar fluid homeostasis via regulation of alveolar epithelial tight junction composition and therefore ion transport and solute permeability, potentially via downstream regulation of the actin cytoskeleton organization and beta-2-adrenergic signaling. Required for lung alveolarization and maintenance of the paracellular alveolar epithelial barrier. Acts to maintain epithelial progenitor cell proliferation and organ size, via regulation of YAP1 localization away from the nucleus and thereby restriction of YAP1 target gene transcription. Acts as a negative regulator of RANKL-induced osteoclast differentiation, potentially via relocation of TJP2/ZO-2 away from the nucleus, subsequently involved in bone resorption in response to calcium deficiency. Mediates the osteoprotective effects of estrogen, potentially via acting downstream of estrogen signaling independently of RANKL signaling pathways. CLDN18.2 is the therapeutic target of zolbetuximab (Vyloy).

Note For research use only. This stable cell line expresses GFP as a reporter marker. GFP is expressed independently of the target protein and is not fused to the target protein.
Images
  • HEK293T Human CLDN18.2 Stable Cell Line

    Flow cytometry

    Untransfected cells (blue Histogram) and Transfected cells (Yellow Histogram) were stained with an anti-human CLDN18.2 monoclonal antibody at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.

References
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recommendation

Contact us for custom quotes, bulk requests and any other issues.

Mail: support@abinScience.com

Distributor list